Live Analyst Rating Changes 18433 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Brendan Smith
TD

Brendan Smith

TD Cowen
Wall Street Analyst
★★★★★
#141
on 13Foresight · ranked by our own returns
62%
Success Rate
+29.5%
Average Return
24 of 39 calls profitable · +24.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 62% of Brendan Smith's ratings turned a profit when each position was held for 1 year — averaging +29.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

97 Buy 34 Hold 0 Sell
Brendan's Stock Coverage 26 ratings · 2026-08-06
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AZTA
Azenta
 Aug 05, 2026 HOLD Buy
+56.2% avg upside
13 analysts
$33.00
3.72% Upside
 · ·
CERT
Certara
 Aug 04, 2026 BUY Buy
+63.4% avg upside
22 analysts
$9.00
12.43% Upside
 +3.2% ·
TWST
Twist Bioscience
 Aug 03, 2026 BUY Strong Buy
-20.4% avg upside
14 analysts
$115.00
0.08% Downside
 -1.6% ·
RGEN
Repligen
 Jul 28, 2026 BUY Strong Buy
+11.2% avg upside
25 analysts
$200.00
26.01% Upside
 +6.3% ·
WST
West Pharmaceutical Services
 Jul 23, 2026 BUY Strong Buy
+4.4% avg upside
18 analysts
$410.00
16.85% Upside
 -1.8% ·
BLFS
BioLife Solutions
 Jul 23, 2026 HOLD Buy
-11.5% avg upside
17 analysts
$31.00
8.23% Downside
 +1.7% ·
EVO
Evotec AG
 Jul 15, 2026 HOLD Buy
+325.1% avg upside
9 analysts
$2.00
0.96% Upside
 -4.0% ·
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
 Jul 14, 2026 HOLD Hold
-93.1% avg upside
1 analyst
$2.00
93.10% Downside
 +5.1% ·
SLP
Simulations Plus
 Jul 09, 2026 HOLD Buy
+106.8% avg upside
11 analysts
$16.00
12.58% Downside
 -0.1% ·
RPID
Rapid Micro Biosystems
 May 27, 2026 BUY Strong Buy
+314.7% avg upside
6 analysts
 — +7.6% ·
MXCT
MaxCyte
 May 12, 2026 BUY Buy
+273.9% avg upside
5 analysts
 — +26.5% ·
PASG
Passage Bio
 May 12, 2026 HOLD Buy
+280.9% avg upside
14 analysts
 — -10.7% ·
ABCL
AbCellera Biologics
 May 11, 2026 BUY Strong Buy
+120.6% avg upside
15 analysts
 — +16.0% ·
HALO
Halozyme
 May 11, 2026 BUY Strong Buy
-29.2% avg upside
20 analysts
$96.00
14.90% Upside
 +29.1% ·
CDXS
Codexis
 May 07, 2026 HOLD Strong Buy
+609.0% avg upside
13 analysts
$2.00
37.92% Upside
 -44.6% ·
OABI
OmniAb
 May 07, 2026 BUY Strong Buy
+289.0% avg upside
10 analysts
$3.00
47.77% Upside
 +36.0% ·
CTKB
Cytek Biosciences
 May 07, 2026 HOLD Buy
+35.6% avg upside
5 analysts
$5.00
19.55% Upside
 -13.8% ·
ABSI
AbSci
 May 07, 2026 BUY Strong Buy
+44.3% avg upside
18 analysts
 — +46.1% ·
DNA
Ginkgo Bioworks Holdings
 May 07, 2026 BUY Sell
-16.4% avg upside
5 analysts
$12.00
28.15% Upside
 -9.2% ·
RXRX
Recursion Pharmaceuticals
 May 06, 2026 HOLD Buy
+150.9% avg upside
12 analysts
 — -7.3% ·
TKNO
Alpha Teknova
 May 06, 2026 BUY Strong Buy
+165.3% avg upside
7 analysts
$7.00
24.88% Upside
 +38.7% ·
MASS
908 Devices
 May 06, 2026 BUY Strong Buy
+30.4% avg upside
4 analysts
 — -4.3% ·
SDGR
Schrodinger
 May 05, 2026 BUY Strong Buy
+74.6% avg upside
14 analysts
$20.00
21.87% Upside
 +340.3% ·
ARWR
Arrowhead Pharmaceuticals
 May 13, 2025 BUY Strong Buy
-14.7% avg upside
27 analysts
 — +409.7% ·
DNLI
Denali Therapeutics
 May 06, 2025 BUY Strong Buy
+54.4% avg upside
24 analysts
 — +46.1% ·
NVAX
Novavax
 Nov 12, 2024 HOLD Hold
+201.9% avg upside
20 analysts
$9.00
16.98% Upside
 -14.9% ·
🔒 21 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Brendan Smith — Frequently Asked Questions
How accurate are Brendan Smith's stock ratings?
Based on the calls 13Foresight could measure, about 64% of Brendan's ratings were profitable over a one-year hold, with an average return of +29.4% per rating, or +24.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Brendan ranked on 13Foresight?
Brendan Smith is currently ranked #141 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Brendan cover?
Brendan most recently has ratings on AZTA, CERT, TWST, RGEN, WST, BLFS, EVO, EVT, SLP, RPID, MXCT, PASG and 14 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.